Vabrinty Injection, Suspension, Extended Release
NDC Package 85043-030-03
Package Information
Vabrinty (leuprolide acetate) injection is vABRINTY is indicated for the treatment of advanced prostate cancer. This formulation utilizes a injection, suspension, extended release delivery system. Marketed by Uronova Pharmaceuticals, Inc., this product is identified by NDC 85043-030 and is authorized under FDA application NDA021488.
Identification & Billing
- RxCUI: 2720345 - Vabrinty 22.5 MG in 0.375 ML (3 month) Prefilled Syringe
- RxCUI: 2720345 - 0.375 ML leuprolide acetate 60 MG/ML Prefilled Syringe [Vabrinty]
- RxCUI: 2720345 - Vabrinty 22.5 MG per 0.375 ML Prefilled Syringe
- RxCUI: 2720348 - Vabrinty 45 MG in 0.375 ML (6 month) Prefilled Syringe
- RxCUI: 2720348 - 0.375 ML leuprolide acetate 120 MG/ML Prefilled Syringe [Vabrinty]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 85043 - Uronova Pharmaceuticals, Inc.
- 85043-030 - Vabrinty
- 85043-030-03 - 1 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE
- 85043-030 - Vabrinty
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 85043-030-03 identifies a specific commercial package of 1 syringe in 1 carton / .5 ml in 1 syringe of Vabrinty, a human prescription drug labeled by Uronova Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, suspension, extended release is formulated for subcutaneous use and contains leuprolide acetate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Uronova Pharmaceuticals, Inc. on August 04, 2025. The current certification is valid through December 31, 2027.
How is this Uronova Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 85043003003. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.